NasdaqGM - Nasdaq Real Time Price USD

Vaxxinity, Inc. (VAXX)

0.1166

-0.0048

(-3.95%)

At close: April 26 at 4:00 PM EDT

0.1150

-0.00

(-1.37%)

After hours: April 26 at 7:45 PM EDT

Vaxxinity Issues Shareholder Letter

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longe

GlobeNewswire 8 days ago
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Sectio

GlobeNewswire 9 days ago
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company’s clinical data in Parkinson’s diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral Pr

GlobeNewswire last month
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “2024 will prove to be a critical year for Vaxxinity as we refocus our efforts on our neurodegeneration programs and move closer to obtaining our company’s first approval,” said Mei Mei Hu, CEO o

GlobeNewswire last month
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patientsLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson’s disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on A

GlobeNewswire last month
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies dem

GlobeNewswire 2 months ago
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Por

GlobeNewswire 2 months ago
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s ac

GlobeNewswire 2 months ago
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to

GlobeNewswire 3 months ago
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30am PST. About Vaxxinity Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare acr

GlobeNewswire 3 months ago
Vaxxinity to Present at Upcoming November Medical and Investor Conferences

CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. Vaccines Summit – 2023Date: Tuesday, November 14, 2023 Time: 12:20 – 12:40 p.m. (ET)Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizi

GlobeNewswire 5 months ago
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have

GlobeNewswire 5 months ago
Vaxxinity to Present at Upcoming Investor Conferences in September

CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September: H.C. Wainwright 25th Annual Global Investment ConferenceDate: Monday, September 11, 2023Time: 5:00 – 5:30 p.m. (ET)Format: Corporate Presentation A live webcast of t

GlobeNewswire 7 months ago
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic UB-311 could offer multiple competitive advantages over licensed passive immunotherapies, including less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of ARIA-E CAPE CANAVERAL, Fla., Aug. 10, 2023 (GLOBE NEWSW

GlobeNewswire 8 months ago
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. “Vaxxinity has broken new ground in the first half of 2023. Now in three independent programs, UB-311, UB-312, and UB-313, we have demonstrated proof of technology and our ability to safely induce antibodies in subjects through act

GlobeNewswire 8 months ago
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity’s board of directors.

GlobeNewswire 8 months ago
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients

Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s ability to selectively target aggregated, toxic forms of neurodegenerative proteins CAPE CANAVERAL, Fla., July 17, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced new data from a Phase 1 clinical trial demonst

GlobeNewswire 9 months ago
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further clinical development. CAPE CANAVERAL, Fla., June 22, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines today announced positive results from Part B of its Phase 1 clinical trial

GlobeNewswire 10 months ago
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity corporate headquarters in Cape Canaveral, Fla. Vaxxinity corporate headquarters in Cape Canaveral, Fla. (Photo: Vaxxinity) CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Vaxxinity remains on track to meet critical milestones in 2023, having taken our f

GlobeNewswire 11 months ago

Performance Overview

Return	VAXX	S&P 500
YTD	-86.28%	+6.92%
1-Year	-93.26%	+25.26%
3-Year	--	+9.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vaxxinity, Inc. (VAXX)

Vaxxinity Issues Shareholder Letter

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity to Present at Upcoming Investor Conferences in September

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

Performance Overview